What is claimed is:

1. A medicament for treatment of Fabry disease in a human patient in need thereof, the medicament comprising a therapeutically effective dose of migalastat or a salt thereof, wherein the patient has an α-galactosidase A mutation selected from the group consisting of: A29D, R38S, N53Y, Y88C, V124G, I133F, A143V, Y152N, F159C, A160D, D165N, F169I, L180V, D182G, R196T, W209R, A257T, P259S, G271A, S276T, M290V, A291S, I303T, I303V, L310V, G360A, G360R, G375A, L394P, G411S, and N419D.

2. The medicament of claim 1,
(i) wherein the migalastat or salt thereof is administered to the patient every other day;
(ii) wherein the patient is administered about 100 to about 150 mg free base equivalent of the migalastat or salt thereof every other day;
(iii) wherein the patient is administered about 123 mg free base equivalent of the migalastat or salt thereof every other day;
(iv) wherein the patient is administered about 123 mg of migalastat free base every other day; or
(v) wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.

3. The medicament of claim1,
wherein the migalastat or salt thereof is administered orally or by injection.

4. The medicament of claim 1, wherein the migalastat or salt thereof enhances α-galactosidase A activity.

5. The medicament of claim 1, wherein the patient is male or female.

6. The medicament of claim 1, wherein the mutation is disclosed in a pharmacological reference table.

7. The medicament of claim 6, wherein the pharmacological reference table is provided in a product label for a migalastat product approved for the treatment of Fabry disease, in a product label for GALAFOLD®, or at a website.

8. The medicament of claim 6, wherein the pharmacological reference table is provided at a website, and wherein the website is one or more of www.galafoldamenabilitytable.com or www.fabrygenevariantsearch.com.

9. A medicament of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease, the medicament comprising a therapeutically effective dose of migalastat or a salt thereof, wherein the patient has an α-galactosidase A mutation selected from the group consisting of:A29D, R38S, N53Y, Y88C, V124G, I133F, A143V, Y152N, F159C, A160D, D165N, F169I, L180V, D182G, R196T, W209R, A257T, P259S, G271A, S276T, M290V, A291S, I303T, I303V, L310V, G360A, G360R, G375A, L394P, G411S, and N419D.

10. The medicament of claim 9,
(i) wherein the migalastat or salt thereof is administered to the patient every other day;
(ii) wherein the patient is administered about 100 to about 150 mg free base equivalent of the migalastat or salt thereof every other day;
(iii) wherein the patient is administered about 123 mg free base equivalent of the migalastat or salt thereof every other day
(iv) wherein the patient is administered about 123 mg of migalastat free base every other day; or
(v) wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.

11. The medicament of claim 9, wherein the migalastat or salt thereof is administered orally or by injection.

12. The medicament of claim 9, wherein the patient is male or female.

13. The medicament of claim 9, wherein the mutation is disclosed in a pharmacological reference table.

14. The medicament of claim 13, wherein the pharmacological reference table is provided in a product label for a migalastat product approved for the treatment of Fabry disease, in a product label for GALAFOLD®, or at a website.

15. The medicament of claim 13, wherein the pharmacological reference table is provided at a website, and wherein the website is one or more of www.galafoldamenabilitytable.com or www.fabrygenevariantsearch.com.